Randomized clinical trials have demonstrated that the GnRH antagonist protocol recruits a smaller number of follicles with lower serum oestradiol and, therefore, the risk of OHSS following triggering of final follicular maturation with human choriogonadotropin (hCG) is lower [3]. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.